Spec. Issue 2006 - Article Summary

Back to table of contents Spec. Issue 2006

LD50 testing of Botulinum toxin for use as a cosmetic

Martin L. Stephens1 and Michael Balls2
1Humane Society of the United States, Washington, DC, USA; 2FRAME, Nottingham, UK
Summary
In 2003, the Fund for the Replacement of Animals in Medical Experiments (FRAME) revealed that the potency of botulinum toxin for use as a popular wrinkle treatment is assessed by using the LD50 Test. The endpoint in this mouse-based testing is death through suffocation. In 2004, The Humane Society of the United States (HSUS) sought to work with Allergan, the US-based manufacturer of Botox® Cosmetic, and the U.S. Food and Drug Administration (FDA), on ways to refine, reduce, and replace this LD50 testing. This article summarises The HSUS’s campaign in the United States and provides an update on FRAME’s continuing efforts in Europe.

Nach oben